EMQN CIC is pleased to announce the launch of a new EQA scheme for CYP2C19 Point-of-Care Testing (POCT), suitable for use with the NICE-recommended Genedrive® CYP2C19 ID Kit.
CYP2C19 Point-of-Care Pharmacogenomic EQA Scheme EMQN CIC’s CYP2C19 EQA scheme is designed to support the accurate and timely identification of CYP2C19 variants in acute clinical settings. This ensures that patients—particularly those presenting with recent ischaemic stroke or transient ischaemic attack (TIA)—receive the most appropriate antiplatelet therapy. Identifying CYP2C19 poor or intermediate metabolisers enables tailored clopidogrel prescribing, which may improve clinical […]
The 2026 EQA catalogue is now available
We are proud to present to you the new EQA schemes for 2026, allowing more flexibility, time and cost efficiency, ease of purchase, and more. Our goal is to ensure the highest genomic diagnostic quality from lab to patient, and our updated schemes will help you get there, tailoring our services to your needs. Check our […]
EMQN CIC Contributes to University of Oxford’s MSc in Precision Medicine
EMQN CIC is proud to have contributed educational materials to the University of Oxford’s 2025/2026 MSc in Precision Medicine, delivered by the Department of Oncology. This opportunity reflects our ongoing commitment to supporting high-quality education and best practices in molecular diagnostics.
Microbix Assisting EMQN with Novel Genetic-Test EQA Program
For Rapid Identification of Patients Susceptible to Antibiotic-Induced Hearing Loss MISSISSAUGA, CANADA & MANCHESTER, UK – December 10, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live […]
EMQN launches new EQA scheme for MT-RNR1 POCT for use with the Genedrive® MT-RNR1 ID Kit
EMQN CIC is pleased to announce the launch of a new EQA scheme for MT-RNR1 Point-of-Care Testing (POCT), suitable for use with the NICE-approved Genedrive® MT-RNR1 ID Kit. This scheme is designed to support the accurate identification of patients in acute clinical settings who carry the MT-RNR1 m.1555A>G variant, ensuring they receive alternative antibiotics to prevent hearing loss. This […]
EMQN-ERN GENTURIS: HBOC genetic testing guidelines
EMQN is honoured that ERN GENTURIS has decided to endorse our best practice guidelines: “EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer (HBOC).” ERN GENTURIS is the European Reference Network (ERN) for all patients with rare genetic tumour risk syndromes. A team of assessors, consisting of HBOC experts and an […]